The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 351:713-714 August 12, 2004 Number 7
NextNext

Uracil–Tegafur in Early-Stage Lung Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Kato, H.
-PubMed Citation
To the Editor: Kato et al. (April 22 issue),1 in their randomized study of adjuvant chemotherapy with uracil–tegafur in patients with completely resected stage I adenocarcinoma, found an overall survival benefit in favor of the uracil–tegafur group (P=0.04). However, the difference between the two groups in cancer-free survival was not significant. Therefore, the overall survival benefit in the treatment group may not reflect actual disease-related survival, which is more important in evaluating the effectiveness of chemotherapy.


Ozden Altundag, M.D.
Kadri Altundag, M.D.
Hacettepe University
Ankara 6100, Turkey
kaltunda@hacettepe.edu.tr


Mehmet Gunduz, M.D., Ph.D.
Okayama University Graduate School of Medicine and Dentistry
. . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.